Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The majority of people are familiar with rheumatoid arthritis and osteoarthritis. The new kid on the block, however, is psoriatic arthritis. Find out more about the signs, causes, and treatments of psoriatic arthritis by reading on.
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
Nuclear missile workers are contracting cancer: They blame the bases
2.
Novel Agent for Chronic GVHD Wins FDA Approval
3.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
4.
Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.
5.
Radiation therapy can promote amphiregulin, which increases growth of metastases
1.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
2.
Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives
3.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
4.
The Benefits and Risks of Thrombolytics: A Comprehensive Guide
5.
Liquid Biopsy in Oncology: Innovations in Cancer Detection, Monitoring, and Clinical Use
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Lung Cancer Congress®
3.
Genito-Urinary Oncology Summit 2026
4.
Future NRG Oncology Meeting
5.
ISMB 2026 (Intelligent Systems for Molecular Biology)
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge